Impact Analysis of Covid-19 On Shingles Vaccine Market Rapidly Develop| Zostavax, GlaxoSmithKline

The Zostavax vaccine, licensed by Merck & Co., Inc. in 2006, is an effective vaccine against shingles. The vaccine is intended for the use in population age 50 years and above. The trials of the Zostavax vaccine demonstrated that the vaccine was 64% effective in people aged 60 to 69 years. The effectiveness reduces with increasing age i.e. to 41% for the 70–79 age group, and 18% for those 80 years of age and above. The vaccine was launched in the India market in February 2016, at half the price of the U.S. market. Zostavax, is only shingles vaccine in the market that recorded sales of US$ 749 million in 2015.

Request a sample copy of the report: https://www.coherentmarketinsights.com/insight/request-sample/73

In October 2016, GlaxoSmithKline (GSK), a global leader in vaccines market, filed for U.S. FDA approval for its shingles vaccine, ‘Shingrix’. Shingrix has demonstrated better outcomes than Zostavax in its clinical trials. The vaccine was 90% effective in people over 70 years of age. The overall effectiveness of the vaccine was found to be 97%. Its higher effectiveness even among geriatric population is projected to increase its adoption across the globe. This impressive trail results would put Shingrix in a strong competitive position in the global market, currently monopolized by Zostavax. The company is reported to have filed for regulatory approvals in the Europe and Canada markets in 2016, followed by Japan in 2017. It is estimated that the sales of Shingrix would reach US$ 1 billion by 2021.

The global shingles vaccine market is witnessing rapid influx of newer and expensive products. The industry is consolidated in nature however, new entrants are expected to emerge in the near future.

Prevalence of shingles is increasing across the globe, fueled mainly by increasing geriatric population. However, high cost of vaccines is limiting vaccination in emerging economies, characterized by inadequate insurance coverage. The major concern among healthcare experts is reduction in postherpetic neuralgia from the shingles vaccine. Zostavax has been successful to a certain extent in reducing postherpetic neuralgia due to the effect of the vaccine on reducing risk of developing herpes zoster. Better outcomes of Shingrix would be a boon for highly lucrative global shingles vaccines market.

Research purpose:

– Provides strategic profiling of key players in the market, comprehensively analyzes core competencies, and derives the competitive landscape of the market.

– Provides insight into factors influencing market growth. Shingles Vaccines market analysis based on various factors such as price analysis, supply chain analysis, Porter Five Force analysis, etc.

– It provides detailed analysis of the market structure with forecasts for various segments and sub-segments of the global Shingles Vaccines market.

– Provides a country level analysis of the market in relation to its current market size and future outlook.

– Provides country-level analysis of the market by application, product type and sub-segment.

– Provides historical and forecast revenue for the market segment and sub-segments in relation to the four major regions and countries in North America, Europe, Asia and other countries.

– Track and analyze competitive developments such as joint ventures, strategic alliances, new product development and research and development in the global Shingles Vaccines Market.

Apply Promo Code “CHRISTMAS2020” And Get Instant Discount of USD 1000

**Note: Year End Discount

If you purchase the report this year:

Flat 20% instant discount

25% discount on 2nd report

15 % free customization

Buy This Complete A Business Report: https://www.coherentmarketinsights.com/insight/buy-now/73

The chapters covered in the research report are as follows:

Chapter 1, 2: Targets of the Global Shingles Vaccines Market, encompassing market introduction, product images, market summary, and development scope.

Chapter 3, Chapter 4: Global Market Competition, Sales Volume, and Market Profit by Manufacturer.

Chapters 5, 6, 7: Global Supply (Production), Consumption, Exports, Imports by Regions such as USA, Asia Pacific, China, India, Japan. From 2015 to 2024, we conduct regional market research based on regional sales rate and market share.

Chapters 8, 9, 10: Global Market Analysis by Application, Cost Analysis, Marketing Strategy Analysis, Distributor/Trader

Chapters 11, 12: Market Information and Research Conclusions, Appendix and Data Sources.

The market report also primarily identifies additional useful and useful information about the industry, including the Shingles Vaccines market development trends analysis, return on investment, and feasibility analysis. Additionally, SWOT analysis is distributed in the report to analyze the growth of key global market players in the Shingles Vaccines market industry.

Contact us for any query or to get a personalized report: https://www.coherentmarketinsights.com/insight/request-customization/73

In addition, the research report investigates:

Competitors and manufacturers in the global market

By product type, application and growth factor

Industry status and outlook for major applications / end users / usage areas

Thanks for reading this article. You can also get individual chapter sections, such as North America, Europe, or Asia, or regional versions of the report.

Coherent Market Insights 1001 4th Ave,
#3200 Seattle, WA 98154,U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.